S H Ferris

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi request reprint ADCS Prevention Instrument Project: overview and initial results
    Steven H Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
    Alzheimer Dis Assoc Disord 20:S109-23. 2006
  2. ncbi request reprint A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI)
    Steven Ferris
    Alzheimer s Disease Center, Silberstein Institute, New York University School of Medicine, New York, NY 10016, USA
    Int J Geriatr Psychiatry 22:448-55. 2007
  3. ncbi request reprint General measures of cognition
    Steven H Ferris
    Silberstein Institute for Aging and Dementia, New York University School of Medicine, New York 10016, USA
    Int Psychogeriatr 15:215-7. 2003
  4. ncbi request reprint Evaluation of memantine for the treatment of Alzheimer's disease
    Steven H Ferris
    Alzheimer s Disease Center, Silberstein Institute for Ageing and Dementia, New York University School of Medicine, 550 First Avenue, Room MHL 310, New York, NY 10016, USA
    Expert Opin Pharmacother 4:2305-13. 2003
  5. ncbi request reprint Differential diagnosis and clinical assessment of patients with severe Alzheimer disease
    Steven H Ferris
    Silberstein Institute for Aging and Dementia, Department of Psychiatry, New York University School of Medicine, New York, New York, USA
    Alzheimer Dis Assoc Disord 17:S92-5. 2003
  6. ncbi request reprint Clinical trials in AD: are current formats and outcome measures adequate?
    Steven H Ferris
    New York University School of Medicine, New York 10016, USA
    Alzheimer Dis Assoc Disord 16:S13-7. 2002
  7. ncbi request reprint Switching previous therapies for Alzheimer's disease to galantamine
    S H Ferris
    Silberstein Aging and Dementia Research Center, Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    Clin Ther 23:A3-7. 2001
  8. ncbi request reprint Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability
    I M Monteiro
    Aging and Dementia Research Center, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Eur Psychiatry 16:5s-24s. 2001
  9. ncbi request reprint Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging
    L S Prichep
    Brain Research Laboratories, Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neurobiol Aging 27:471-81. 2006
  10. ncbi request reprint A visual recognition memory test for the assessment of cognitive function in aging and dementia
    C Flicker
    Department of Psychiatry, New York University Medical Center, NY 10016
    Exp Aging Res 13:127-32. 1987

Detail Information

Publications28

  1. ncbi request reprint ADCS Prevention Instrument Project: overview and initial results
    Steven H Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
    Alzheimer Dis Assoc Disord 20:S109-23. 2006
    ..Initial results for the experimental instruments and for the book club are reported in separate accompanying articles...
  2. ncbi request reprint A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI)
    Steven Ferris
    Alzheimer s Disease Center, Silberstein Institute, New York University School of Medicine, New York, NY 10016, USA
    Int J Geriatr Psychiatry 22:448-55. 2007
    ..To determine the safety and efficacy of memantine in treating Age-Associated Memory Impairment (AAMI)...
  3. ncbi request reprint General measures of cognition
    Steven H Ferris
    Silberstein Institute for Aging and Dementia, New York University School of Medicine, New York 10016, USA
    Int Psychogeriatr 15:215-7. 2003
    ..Validation of this new cognitive instrument will be supported by its successful use in vascular dementia clinical trials...
  4. ncbi request reprint Evaluation of memantine for the treatment of Alzheimer's disease
    Steven H Ferris
    Alzheimer s Disease Center, Silberstein Institute for Ageing and Dementia, New York University School of Medicine, 550 First Avenue, Room MHL 310, New York, NY 10016, USA
    Expert Opin Pharmacother 4:2305-13. 2003
    ..This review provides a brief rationale for the development of memantine as a therapy for AD, as well as an overview of the pharmacology, clinical efficacy, safety and tolerability of this novel therapeutic agent...
  5. ncbi request reprint Differential diagnosis and clinical assessment of patients with severe Alzheimer disease
    Steven H Ferris
    Silberstein Institute for Aging and Dementia, Department of Psychiatry, New York University School of Medicine, New York, New York, USA
    Alzheimer Dis Assoc Disord 17:S92-5. 2003
    ..Accurate diagnosis and continued evaluation of these aspects of AD can help guide therapy for patients in the late stage of the disease. Assessment tools specific for patients with severe AD are available for use in clinical studies...
  6. ncbi request reprint Clinical trials in AD: are current formats and outcome measures adequate?
    Steven H Ferris
    New York University School of Medicine, New York 10016, USA
    Alzheimer Dis Assoc Disord 16:S13-7. 2002
    ..Research to develop more efficient assessment methods is clearly needed. Data acquisition over the Internet is potentially efficient and attractive and may become practical as Internet accessibility increases...
  7. ncbi request reprint Switching previous therapies for Alzheimer's disease to galantamine
    S H Ferris
    Silberstein Aging and Dementia Research Center, Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    Clin Ther 23:A3-7. 2001
    ..These findings suggest that discontinuation of prior AChEI treatment is not predictive of future poor response to an effective treatment...
  8. ncbi request reprint Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability
    I M Monteiro
    Aging and Dementia Research Center, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Eur Psychiatry 16:5s-24s. 2001
    ..69 to 0.98 for the seven symptom categories (p(s) < 0.001). For the BEHAVE-AD-FW total scores, the ICC was 0.91 (P < 0.001). These results indicate that the frequency-weighted component is a reliable addition to the BEHAVE-AD scale...
  9. ncbi request reprint Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging
    L S Prichep
    Brain Research Laboratories, Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neurobiol Aging 27:471-81. 2006
    ..These data indicate high sensitivity and specificity for baseline QEEG as a differential predictor of future cognitive state in normal, subjectively impaired elderly...
  10. ncbi request reprint A visual recognition memory test for the assessment of cognitive function in aging and dementia
    C Flicker
    Department of Psychiatry, New York University Medical Center, NY 10016
    Exp Aging Res 13:127-32. 1987
    ..Thus, although the task does not appear to be suitable for diagnostic purposes it would be useful for the assessment of treatment effects upon age-related cognitive dysfunction...
  11. ncbi request reprint ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Alzheimer Dis Assoc Disord 20:S124-38. 2006
    ..An important consideration was whether global assessments are specific and sensitive measures of change during a prevention trial...
  12. ncbi request reprint ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials
    David P Salmon
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
    Alzheimer Dis Assoc Disord 20:S139-46. 2006
    ....
  13. ncbi request reprint ADCS Prevention Instrument Project: behavioral measures in primary prevention trials
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:S147-51. 2006
    ..Experimental behavioral measures were included in the protocol to examine this hypothesis...
  14. doi request reprint Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease
    Roger Lane
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Pharmacogenet Genomics 18:289-98. 2008
    ..To evaluate the synergistic effects of the apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI)...
  15. ncbi request reprint Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial
    Paul S Aisen
    Georgetown University Medical Center, Washington, DC, USA
    Curr Alzheimer Res 5:73-82. 2008
    ..The significance of the observation that rofecoxib increased the rate of conversion from MCI to AD remains uncertain...
  16. pmc ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly
    Mary Sano
    Mount Sinai School of Medicine, James J Peters VAMC, Bronx, NY 10468, USA
    Alzheimer Dis Assoc Disord 20:S191-202. 2006
    ..In addition, the loss that relates to the subjects' own time as they transition through cognitive impairment is not well documented...
  17. ncbi request reprint Mild cognitive impairment (MCI): a historical perspective
    Barry Reisberg
    Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA
    Int Psychogeriatr 20:18-31. 2008
    ..Nevertheless, longitudinal and other studies indicate essential compatibility between GDS stage 3 MCI and Petersen's MCI duration and outcomes...
  18. ncbi request reprint Supplement editorial: alzheimer disease
    Steven H Ferris
    Alzheimer Dis Assoc Disord 20:S107-8. 2006
  19. ncbi request reprint Staging: relevance for trial design in vascular burden of the brain
    Barry Reisberg
    William and Sylvia Silberstein Aging and Dementia Research Center, New York University School of Medicine, NY 10016, USA
    Int Psychogeriatr 15:231-9. 2003
    ..Although temporal and prognostic aspects have been studied for the Alzheimer's-related portions of this clinical staging continuum, they remain to be elucidated for cerebrovascular small vessel disease...
  20. pmc High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
    ..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
  21. ncbi request reprint Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla 92093 0949, USA
    J Mol Neurosci 20:241-8. 2003
    ..We conclude that the relationship between hippocampal volume and risk of AD is likely tied to reduced memory performance and not associated with impairment in nonmemory cognitive domains...
  22. ncbi request reprint Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  23. ncbi request reprint A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment
    Leon J Thal
    University of California, San Diego, CA, USA
    Neuropsychopharmacology 30:1204-15. 2005
    ..In conjunction with the lack of effects observed in previous AD studies, the findings suggest that inhibition of COX-2 is not a useful therapeutic approach in AD...
  24. ncbi request reprint Effects of N-PEP-12 on memory among older adults
    Thomas H Crook
    Psychologix, Inc, Fort Lauderdale, FL 33308, USA
    Int Clin Psychopharmacol 20:97-100. 2005
    ..N-PEP-12 may be an effective treatment for memory loss in healthy older adults...
  25. ncbi request reprint Barriers to drug discovery and development for Alzheimer disease
    Howard M Fillit
    The Institute for the Study of Aging, Inc, New York, New York, USA
    Alzheimer Dis Assoc Disord 16:S1-8. 2002
    ..The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail...
  26. ncbi request reprint A phase I study of AIT-082 in healthy elderly volunteers
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla 92037, USA
    J Mol Neurosci 18:283-93. 2002
    ..In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated...
  27. ncbi request reprint Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
    Tony Waegemans
    Research and Development, UCB SA Pharma Sector, Braine l Alleud, Belgium
    Dement Geriatr Cogn Disord 13:217-24. 2002
    ....
  28. ncbi request reprint Recommendations for best practices in the treatment of Alzheimer's disease in managed care
    Howard M Fillit
    Alzheimer s Drug Discovery Foundation and Institute for the Study of Aging New York, New York 10019, USA
    Am J Geriatr Pharmacother 4:S9-S24; quiz S25-S28. 2006
    ..However, these clinical guidelines have not been updated in the past few years...